Therapy-Related Leukemia following Docetaxel Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.

ABSTRACT:

Introduction

Docetaxel is the first-line drug that has been proved to improve the overall survival of men with metastatic hormone-sensitive prostate cancer (mHSPC). For patients who survive the prostate cancer, they may be at risk of secondary neoplasm, especially for the therapy-related myelodysplastic syndrome or therapy-related acute myeloid leukemia (t-AML).

Case presentation

We reported a 44-year-old man with prostate cancer (cT4N1M1c) who developed t-AML following docetaxel chemotherapy. Typically, the t-AML in our case was characterized by an aberrant karyotype t(15;17)(q22;q21).

Conclusions

This case is, to our knowledge, the first time to report a patient with mHSPC who developed therapy-related acute promyelocytic leukemia following docetaxel chemotherapy, s

SUBMITTER: Zhu C 

PROVIDER: S-EPMC11731904 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature